{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"6"}]}],"title":"Any Treatment Emergent Adverse Event (TEAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"2"}]}],"title":"Zanidatamab related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"3"}]}],"title":"Any Treatment Emergent Serious Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}]}],"title":"Zanidatamab related serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"title":"Zanidatamab related TEAE resulting in treatment discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Number of subjects who experienced AEs or serious adverse events","groups":[{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by in situ hybridization (ISH) and HER2 overexpression by immunohistochemistry (IHC) which includes IHC 2+ or 3+","id":"OG000","title":"Cohort I"},{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by ISH and HER2 IHC 0 or 1+.","id":"OG001","title":"Cohort II"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Incidence of Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}